39
Participants
Start Date
January 22, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
July 31, 2027
AOC 1044
AOC 1044 will be administered via intravenous (IV) infusion
Rare Disease Research, Hillsborough
Rare Disease Research - Atlanta, Atlanta
Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus
Gillette Children's Specialty Healthcare, Saint Paul
Arkansas Children's Hospital, Little Rock
Neurology Rare Disease Center, Denton
University of California, San Diego, Rady's Children's Hospital, La Jolla
Lucille Packard Children's Hospital at Stanford, San Carlos
UC Davis Medical Center, Sacramento
University of Massachusetts Medical School, Worcester
Lead Sponsor
Avidity Biosciences, Inc.
INDUSTRY